Borges Nicolas Henrique, Suss Paula Hansen, Ortis Gabriel Burato, Dantas Leticia Ramos, Tuon Felipe Francisco
Laboratory of Emerging Infectious Diseases, School of Medicine, Pontifícia Universidade Católica do Paraná, Curitiba 80215-901, Brazil.
Microorganisms. 2025 May 13;13(5):1119. doi: 10.3390/microorganisms13051119.
are frequently associated with biofilm formation on intravascular devices. Biofilms limit antimicrobial penetration and promote phenotypic resistance, challenging conventional treatment strategies. Vancomycin (VAN) and gentamicin (GEN) have been used clinically, but their combined antibiofilm activity remains underexplored. This study evaluates the efficacy of VAN and GEN, alone and in combination, against biofilms formed by methicillin-resistant (MRSA) and methicillin-sensitive (MSSA) on polyurethane. MICs were determined for VAN and GEN. Biofilm biomass and metabolic activity were quantified using crystal violet and MTT assays, respectively. Biofilm viability was assessed through fluorescence microscopy and a modified Calgary Biofilm Device. A continuous-flow peristaltic model was developed to test treatment under simulated catheter conditions. While monotherapy with VAN or GEN had modest effects, their combination significantly reduced biomass and metabolic activity. VAN 20 mg/L + GEN 8 mg/L and VAN 40 mg/L + GEN 8 mg/L achieved over 70% reduction in MRSA biofilm viability and complete eradication in MBEC assays. Dynamic model assays confirmed biofilm reduction with combination therapy. The combination of VAN/GEN exhibits synergistic antibiofilm activity against , particularly MRSA. These findings support its potential application in catheter salvage strategies, including antibiotic lock therapy.
常与血管内装置上的生物膜形成相关。生物膜会限制抗菌药物的渗透并促进表型耐药,对传统治疗策略构成挑战。万古霉素(VAN)和庆大霉素(GEN)已在临床上使用,但其联合抗生物膜活性仍未得到充分研究。本研究评估了VAN和GEN单独及联合使用对耐甲氧西林金黄色葡萄球菌(MRSA)和甲氧西林敏感金黄色葡萄球菌(MSSA)在聚氨酯上形成的生物膜的疗效。测定了VAN和GEN的最低抑菌浓度(MIC)。分别使用结晶紫和MTT法对生物膜生物量和代谢活性进行定量。通过荧光显微镜和改良的卡尔加里生物膜装置评估生物膜活力。开发了一种连续流动蠕动模型以在模拟导管条件下测试治疗效果。虽然单独使用VAN或GEN进行单药治疗效果一般,但它们的联合使用显著降低了生物量和代谢活性。在MBEC试验中,VAN 20 mg/L + GEN 8 mg/L和VAN 40 mg/L + GEN 8 mg/L使MRSA生物膜活力降低超过70%并实现完全根除。动态模型试验证实联合治疗可减少生物膜。VAN/GEN联合对[此处原文缺失具体菌株名称],特别是MRSA表现出协同抗生物膜活性。这些发现支持了其在导管挽救策略中的潜在应用,包括抗生素封管疗法